- Home
- TARS vs IHS Comparison
TARS vs IHS Comparison
Compare TARS & IHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- IHS
- Stock Information
- Founded
- TARS 2016
- IHS 2001
- Country
- TARS United States
- IHS United Kingdom
- Employees
- TARS N/A
- IHS N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- IHS Telecommunications Equipment
- Sector
- TARS Health Care
- IHS Telecommunications
- Exchange
- TARS Nasdaq
- IHS Nasdaq
- Market Cap
- TARS 2.8B
- IHS 2.3B
- IPO Year
- TARS 2020
- IHS 2021
- Fundamental
- Price
- TARS $77.39
- IHS $6.31
- Analyst Decision
- TARS Strong Buy
- IHS Buy
- Analyst Count
- TARS 7
- IHS 7
- Target Price
- TARS $69.86
- IHS $9.04
- AVG Volume (30 Days)
- TARS 461.9K
- IHS 585.7K
- Earning Date
- TARS 11-04-2025
- IHS 11-12-2025
- Dividend Yield
- TARS N/A
- IHS N/A
- EPS Growth
- TARS N/A
- IHS N/A
- EPS
- TARS N/A
- IHS 1.37
- Revenue
- TARS $366,100,000.00
- IHS $1,765,825,000.00
- Revenue This Year
- TARS $139.46
- IHS $2.15
- Revenue Next Year
- TARS $49.91
- IHS $5.32
- P/E Ratio
- TARS N/A
- IHS $4.60
- Revenue Growth
- TARS 182.44
- IHS N/A
- 52 Week Low
- TARS $38.51
- IHS $2.71
- 52 Week High
- TARS $78.76
- IHS $8.00
- Technical
- Relative Strength Index (RSI)
- TARS 66.65
- IHS 42.38
- Support Level
- TARS $70.84
- IHS $6.07
- Resistance Level
- TARS $78.76
- IHS $8.00
- Average True Range (ATR)
- TARS 3.29
- IHS 0.38
- MACD
- TARS 0.35
- IHS -0.04
- Stochastic Oscillator
- TARS 88.54
- IHS 25.98
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.